.Pharmacolibrary.Drugs.ATC.N.N07XX05 .Pharmacolibrary.Drugs.ATC.N.N07XX05| name: | Amifampridine |
| ATC code: | N07XX05 | route: | oral |
| n-compartments | 1 |
Amifampridine (3,4-diaminopyridine) is a potassium channel blocker used primarily in the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder. It is also investigated in other disorders with neuromuscular transmission impairment. The drug is currently approved in the US and EU for use in LEMS.
Pharmacokinetic parameters reported for adult patients with LEMS, both sexes, following oral administration as immediate-release formulation.
Haroldsen, PE, et al., & O'Neill, CA (2015). Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults. Clinical therapeutics 37(7) 1555–1563. DOI:10.1016/j.clinthera.2015.05.498 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26101174
Ishida, N, et al., & Komai, K (2015). Pharmacokinetics and safety of 3,4-diaminopyridine base in healthy Japanese volunteers. International journal of clinical pharmacology and therapeutics 53(8) 674–680. DOI:10.5414/CP202133 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26152130